Literature DB >> 6256335

Biological activity of a new class of rifamycins. Spiro-piperidyl-rifamycins.

A Sanfilippo, C Della Bruna, L Marsili, E Morvillo, C R Pasqualucci, G Schioppacassi, D Ungheri.   

Abstract

The biological properties of spiro-piperidyl-rifamycins, a new class of rifamycin antibiotics, are described. In these derivatives the positions 3 and 4 have been incorporated into an imidazolyl ring bearing a spiro-piperidyl group N substituted with linear and branched aliphatic chains. The in vitro antibacterial activity against Staphylococcus aureus and Mycobacterium tuberculosis increases with the number of the carbon atoms in the linera side chain, whereas the inhibitory effect on Escherichia coli is lowered. The antibacterial activity is only marginally affected by branching of the side chain. In vivo (experimental infections of mice) the optimal therapeutic activity against M. tuberculosis is shown by compounds bearing 3 approximately 5 carbon atoms as a linear or branched side chain; in comparison with rifampicin, the potency of these derivatives is 2 approximately 3 times higher. The finding is in a good agreement with the exceptional tissue tropism, which seems to be a favourable property of this group of derivatives.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6256335     DOI: 10.7164/antibiotics.33.1193

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  8 in total

1.  Rifabutin and rifapentine compared with rifampin against Mycobacterium leprae in mice.

Authors:  S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

2.  Susceptibilities of transparent, opaque, and rough colonial variants of Mycobacterium avium complex to various fatty acids.

Authors:  H Saito; H Tomioka
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

Review 3.  Antimicrobial agent resistance in mycobacteria: molecular genetic insights.

Authors:  J M Musser
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

4.  6S RNA-Dependent Susceptibility to RNA Polymerase Inhibitors.

Authors:  Marick Esberard; Marc Hallier; Wenfeng Liu; Claire Morvan; Lionello Bossi; Nara Figueroa-Bossi; Brice Felden; Philippe Bouloc
Journal:  Antimicrob Agents Chemother       Date:  2022-04-07       Impact factor: 5.938

5.  In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis.

Authors:  T Yamamoto; R Amitani; K Suzuki; E Tanaka; T Murayama; F Kuze
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

6.  Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods.

Authors:  L B Heifets; M D Iseman; P J Lindholm-Levy; W Kanes
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

7.  Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.

Authors:  Suhashni Naiker; Cathy Connolly; Lubbe Wiesner; Tracey Kellerman; Tarylee Reddy; Anthony Harries; Helen McIlleron; Christian Lienhardt; Alexander Pym
Journal:  BMC Pharmacol Toxicol       Date:  2014-11-19       Impact factor: 2.483

8.  A Semisynthetic Kanglemycin Shows In Vivo Efficacy against High-Burden Rifampicin Resistant Pathogens.

Authors:  James Peek; Jiayi Xu; Han Wang; Shraddha Suryavanshi; Matthew Zimmerman; Riccardo Russo; Steven Park; David S Perlin; Sean F Brady
Journal:  ACS Infect Dis       Date:  2020-08-25       Impact factor: 5.084

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.